A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

  • STATUS
    Recruiting
  • End date
    Jan 14, 2024
  • participants needed
    6
  • sponsor
    Clinuvel Europe Limited
Send
Updated on 14 October 2022
See if I qualify

Summary

The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.

Details
Condition Xeroderma Pigmentosum
Treatment Afamelanotide
Clinical Study IdentifierNCT05159752
SponsorClinuvel Europe Limited
Last Modified on14 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female patient with a molecular-genetically confirmed diagnosis of XP-C
Aged 18-75 years

Exclusion Criteria

Known allergy to afamelanotide or the polymer contained in the implant
Presence of severe hepatic disease or hepatic impairment
Renal impairment
Any other medical condition which may interfere with the study protocol
Female who is pregnant (confirmed by positive urine beta-Human chorionic gonadotropin pregnancy test) or lactating
Females of child-bearing potential (pre-menopausal, not surgically sterile) not using highly effective contraceptive measures with a failure rate of less than 1% per year when used consistently and correctly (i.e. oral contraceptives, intrauterine device) or a life-style excluding pregnancy, for up to three months after the last implant administration
Sexually active man with a partner of child-bearing potential (pre-menopausal, not surgically sterile) who is not using highly effective contraceptive measures, as described above
Use of any other prior and concomitant therapy which may interfere with the objective of the study, within 30 days prior to the Screening visit
Participation in a clinical trial for an investigational agent within 30 days prior to the Screening visit
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note